Skip to content

10x Genomics, Inc. TXG Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$1K
Repligen logo
RepligenRGEN
$564K+0.4%
TEC
Bio-TechneTECH
Illumina logo
IlluminaILMN
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$150.8M-2.6%
Gross profit$106.2M+0.7%
Operating income-$17.0M+56.7%
Net income-$13.5M+60.8%
EPS (diluted)-$0.10+64.3%

Balance sheet

See full
Cash & equivalents$490.3M+30.0%
Total debt$81.4M+1.6%
Total equity$814.3M+15.2%
Total assets$1.0B+12.4%

Cash flow

See full
Operating cash flow$26.1M-24.0%
CapEx$1.6M-15.6%
Free cash flow$24.5M-24.4%

Valuation

See full
Market cap$4.41B+154%

Profitability

See full
Gross margin69.6%+1.2pp
Operating margin-6.1%-2.7pp
Net margin-3.5%-1.6pp
FCF margin19.1%

Returns & leverage

See full
Return on equity-3%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 10x Genomics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
10x Genomics, Inc. (TXG) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $2K in Q1 2026.
How has 10x Genomics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
10x Genomics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively decreased by 0.0% year-over-year, from $2K to $2K.
What is the long-term trend for 10x Genomics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Over 5 years (2020 to 2025), 10x Genomics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a 0.0% compound annual growth rate (CAGR), from $2K to $2K.
What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
This represents the par value of the common shares issued and outstanding. It is a foundational component of shareholders' equity and reflects the legal capital contributed by shareholders. While often small in dollar terms, it tracks the number of shares issued and the company's basic ownership structure.